The Effect of Sex on Disease Stage and Survival after Radical Cystectomy in Non-Urothelial Variant-Histology Bladder Cancer
Rocco Simone Flammia(National Cancer Institute), Pierre I. Karakiewicz(Université de Montréal), Christoph Würnschimmel(Universität Hamburg), Zhen Tian(Université de Montréal), Antonio Giordano(University of Siena), Umberto Anceschi(Istituti di Ricovero e Cura a Carattere Scientifico), Alberto Briganti(University College London Hospitals NHS Foundation Trust), Carlo Terrone(University of Turin), Fred Saad(Centre Hospitalier de l’Université de Montréal), Francesco Chierigo(Université de Montréal), Andrea Morrione(Temple University), Francesco Montorsi(Vita-Salute San Raffaele University), Antonio Tufano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Shahrokh F. Shariat(Universitätszahnklinik Wien), Costantino Leonardo(Policlinico Umberto I), Michele Gallucci(Unknown), Benedikt Hoeh(Goethe University Frankfurt), Gabriele Sorce(University of Messina), Francesco Del Giudice(Sapienza University of Rome), Felix K.‐H. Chun(Universität Hamburg)
Cited by 12
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
2007 Guideline for the Management of Ureteral Calculi
|European Urology|2007|1.1k